This inventor holds 1 USPTO granted patent and 2 published patent applications, plus 1 CIPO patent and 1 EPO patent. Top assignee: Vascular Biogenics Ltd.. Active years: 2019.
Company Filing History:
Years Active: 2019
Title: Innovations by Andrew J Brenner in Glioblastoma Treatment
Introduction
Andrew J Brenner is an accomplished inventor based in Boerne, TX (US). He has made significant contributions to the field of medical research, particularly in the treatment of glioblastoma, a highly aggressive form of brain cancer. His innovative approaches aim to improve therapeutic outcomes for patients suffering from this challenging condition.
Latest Patents
Andrew J Brenner holds a patent for "Compositions and methods for treating glioblastoma GBM." This patent outlines methods for treating malignant glioma in subjects by administering a therapeutically effective amount of a viral vector. The viral vector includes a first polynucleotide sequence encoding a Fas-chimera and a second polynucleotide sequence encoding an endothelial cell-specific promoter or a periendothelial cell-specific promoter. This innovative method represents a promising advancement in glioblastoma treatment.
Career Highlights
Throughout his career, Andrew J Brenner has focused on developing novel therapeutic strategies for cancer treatment. His work has been instrumental in advancing the understanding of glioblastoma and exploring new avenues for effective treatment options. His dedication to research and innovation has positioned him as a key figure in the medical community.
Collaborations
Andrew J Brenner has collaborated with notable professionals in his field, including Yael Cohen and Livnat Bangio. These partnerships have fostered a collaborative environment that enhances the development of innovative solutions for glioblastoma treatment.
Conclusion
In summary, Andrew J Brenner's contributions to glioblastoma treatment through his innovative patent and collaborative efforts highlight his commitment to advancing medical research. His work continues to inspire progress in the fight against this aggressive cancer.